Focused On-demand Library for Melanophilin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BV36

UPID:

MELPH_HUMAN

Alternative names:

Exophilin-3; Slp homolog lacking C2 domains a; Synaptotagmin-like protein 2a

Alternative UPACC:

Q9BV36; B3KSS2; B4DKW7; G5E9G5; Q9HA71

Background:

Melanophilin, also known as Exophilin-3, Slp homolog lacking C2 domains a, and Synaptotagmin-like protein 2a, plays a pivotal role in melanosome transport. It acts as a crucial link between melanosome-bound RAB27A and the motor protein MYO5A, facilitating the movement of melanosomes within cells.

Therapeutic significance:

Melanophilin's dysfunction is directly linked to Griscelli syndrome 3, a rare autosomal recessive disorder characterized by pigmentary dilution of the skin and hair. Understanding the role of Melanophilin could open doors to potential therapeutic strategies for this condition.